145 related articles for article (PubMed ID: 37294924)
1. Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models.
Jiang M; Yang F; Jiang Y; Cheng L; Han J; Yi J; Zuo B; Huang L; Ma Z; Li T; Cao LJ; Xia Z; Bai X; Jia C; Yang TTC; Esmon NL; Ruan C; Xia L; Esmon CT; Han Y; Wu D; Xu J
Blood; 2023 Sep; 142(12):1071-1081. PubMed ID: 37294924
[TBL] [Abstract][Full Text] [Related]
2. Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C.
Jiang M; Yang F; Jiang Y; Cheng L; Han J; Yi J; Zhang G; Ma Z; Cao L; Zuo B; Zhou L; Huang L; Niu S; Xia Z; Zhou X; Bai X; Esmon NL; Ruan C; Xia L; Han Y; Esmon CT; Wu D; Xu J
Blood Adv; 2022 Jun; 6(11):3304-3314. PubMed ID: 35390147
[TBL] [Abstract][Full Text] [Related]
3. Targeting activated protein C to treat hemophilia.
Polderdijk SGI; Baglin TP; Huntington JA
Curr Opin Hematol; 2017 Sep; 24(5):446-452. PubMed ID: 28632502
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy in mice.
Magisetty J; Kondreddy V; Keshava S; Das K; Esmon CT; Pendurthi UR; Rao LVM
Blood; 2022 May; 139(18):2830-2841. PubMed ID: 35143636
[TBL] [Abstract][Full Text] [Related]
5. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
Lauritzen B; Olling J; Abel KL; Augustsson C; Balling K; Bjelke M; Hegelund AC; Hilden I
J Thromb Haemost; 2019 Mar; 17(3):460-469. PubMed ID: 30614620
[TBL] [Abstract][Full Text] [Related]
6. An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C.
von Drygalski A; Bhat V; Gale AJ; Burnier L; Cramer TJ; Griffin JH; Mosnier LO
PLoS One; 2014; 9(8):e104304. PubMed ID: 25127130
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
[TBL] [Abstract][Full Text] [Related]
8. Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors.
Barbon E; Ayme G; Mohamadi A; Ottavi JF; Kawecki C; Casari C; Verhenne S; Marmier S; van Wittenberghe L; Charles S; Collaud F; Denis CV; Christophe OD; Mingozzi F; Lenting PJ
EMBO Mol Med; 2020 Apr; 12(4):e11298. PubMed ID: 32159286
[TBL] [Abstract][Full Text] [Related]
9. Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke.
Williams PD; Zlokovic BV; Griffin JH; Pryor KE; Davis TP
Curr Pharm Des; 2012; 18(27):4215-22. PubMed ID: 22632606
[TBL] [Abstract][Full Text] [Related]
10. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation.
Esmon CT
Crit Care Med; 2001 Jul; 29(7 Suppl):S48-51; discussion 51-2. PubMed ID: 11445734
[TBL] [Abstract][Full Text] [Related]
11. Novel treatments for hemophilia through rebalancing of the coagulation cascade.
Zhao Y; Weyand AC; Shavit JA
Pediatr Blood Cancer; 2021 May; 68(5):e28934. PubMed ID: 33577709
[TBL] [Abstract][Full Text] [Related]
12. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
Ragni MV
Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
[TBL] [Abstract][Full Text] [Related]
13. Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
Girard TJ; Lasky NM; Grunz K; Broze GJ
J Thromb Haemost; 2019 Jan; 17(1):149-156. PubMed ID: 30451376
[TBL] [Abstract][Full Text] [Related]
14. Peptidomimetic inhibitors for activated protein C: implications for hemophilia management.
Butenas S; Orfeo T; Kalafatis M; Mann KG
J Thromb Haemost; 2006 Nov; 4(11):2411-6. PubMed ID: 17059471
[TBL] [Abstract][Full Text] [Related]
15. Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.
Stagaard R; Flick MJ; Bojko B; Goryński K; Goryńska PZ; Ley CD; Olsen LH; Knudsen T
J Thromb Haemost; 2018 Jul; 16(7):1369-1382. PubMed ID: 29758126
[TBL] [Abstract][Full Text] [Related]
16. Activated protein C protects against renal ischaemia/reperfusion injury, independent of its anticoagulant properties.
Lattenist L; Jansen MP; Teske G; Claessen N; Meijers JC; Rezaie AR; Esmon CT; Florquin S; Roelofs JJ
Thromb Haemost; 2016 Jul; 116(1):124-33. PubMed ID: 27052416
[TBL] [Abstract][Full Text] [Related]
17. Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.
von Drygalski A; Cramer TJ; Bhat V; Griffin JH; Gale AJ; Mosnier LO
J Thromb Haemost; 2014; 12(3):363-72. PubMed ID: 24818532
[TBL] [Abstract][Full Text] [Related]
18. Serpins, New Therapeutic Targets for Hemophilia.
Aymonnier K; Kawecki C; Arocas V; Boulaftali Y; Bouton MC
Thromb Haemost; 2021 Mar; 121(3):261-269. PubMed ID: 32987444
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke.
Andreou AP; Efthymiou M; Yu Y; Watts HR; Noormohamed FH; Ma D; Lane DA; Crawley JT
PLoS One; 2015; 10(4):e0122410. PubMed ID: 25830552
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
